SuperworthBiocryst Pharmaceuticals EPS BCRX
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$1.50
- Latest quarter, Q2 FY26
- $0.30
- +1400% on a year earlier
- Fiscal year 2025
- $1.20
Biocryst Pharmaceuticals' earnings per share was −$1.50 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $0.30, up 1400% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $1.20 | n/a |
| FY2024 | −$0.43 | n/a |
| FY2023 | −$1.18 | n/a |
| FY2022 | −$1.33 | n/a |
| FY2021 | −$1.03 | n/a |
| FY2020 | −$1.08 | n/a |
| FY2019 | −$0.98 | n/a |
| FY2018 | −$0.98 | n/a |
| FY2017 | −$0.78 | n/a |
| FY2016 | −$0.75 | n/a |
| FY2015 | −$0.60 | n/a |
| FY2014 | −$0.68 | n/a |
| FY2013 | −$0.55 | n/a |
| FY2012 | −$0.79 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.30 | +1400% | −$1.50 | |
| Q1 FY26 | −$2.98 | n/a | −$1.78 | |
| Q4 FY25 | $1.12 | n/a | $1.20 | |
| Q3 FY25 | $0.06 | n/a | −$0.05 | |
| Q2 FY25 | $0.02 | n/a | −$0.18 | |
| Q1 FY25 | $0.00 | n/a | −$0.26 | |
| Q4 FY24 | −$0.13 | n/a | −$0.43 | |
| Q3 FY24 | −$0.07 | n/a | −$0.61 | |
| Q2 FY24 | −$0.06 | n/a | −$0.73 | |
| Q1 FY24 | −$0.17 | n/a | −$1.07 | |
| Q4 FY23 | −$0.31 | n/a | −$1.18 | |
| Q3 FY23 | −$0.19 | n/a | −$1.25 |
Against its peers
Companies in Biotechnology nearest Biocryst Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BCRXBiocryst Pharmaceuticals | −$1.50 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| MGTXMeiraGTx | $0.71 | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| RGENRepligen | $0.73 | |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| EXELExelixis | $3.18 | +53% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| Peer median | $0.94 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Biocryst Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.